nitazoxanide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiparasitics, salicylanilides and analogues 1943 55981-09-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nitazoxanide
  • nitazode
  • nitazoxanida
  • nizonide
a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug; structure given in first source. It was investigated as a potential treatment for COVID-19 based on its broad antiviral activity, including in vitro activity against SARS-CoV-2 and MERS-CoV; however, there are no data to support the use of nitazoxanide in the treatment of COVID-19.
  • Molecular weight: 307.28
  • Formula: C12H9N3O5S
  • CLOGP: 1.25
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 1
  • TPSA: 114.11
  • ALOGS: -4.61
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 46.49 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 70 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Nov. 22, 2002 FDA ROMARK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy interrupted 341.57 39.47 89 1346 32366 63455221
Death 296.99 39.47 150 1285 374231 63113356
Therapy cessation 210.00 39.47 60 1375 30397 63457190
Hospitalisation 118.95 39.47 51 1384 85030 63402557
Surgery 113.34 39.47 39 1396 35873 63451714
Intentional dose omission 55.85 39.47 16 1419 8059 63479528
Anticholinergic syndrome 47.61 39.47 11 1424 2371 63485216
Chromaturia 44.40 39.47 16 1419 16701 63470886

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 351.45 39.83 175 709 397874 34558173
Therapy interrupted 190.36 39.83 48 836 13649 34942398
Therapy cessation 133.61 39.83 38 846 16935 34939112
Surgery 81.86 39.83 25 859 14132 34941915
Hospitalisation 56.96 39.83 28 856 56874 34899173

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 654.93 33.41 320 2084 566194 79175790
Therapy interrupted 529.61 33.41 133 2271 31208 79710776
Therapy cessation 333.28 33.41 96 2308 37466 79704518
Surgery 200.59 33.41 63 2341 32703 79709281
Hospitalisation 177.75 33.41 76 2328 94160 79647824
Chromaturia 69.75 33.41 27 2377 25719 79716265
Intentional dose omission 62.46 33.41 19 2385 8798 79733186
Anticholinergic syndrome 39.91 33.41 11 2393 3600 79738384
Spinal operation 39.24 33.41 13 2391 7904 79734080

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC P01AX11 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
Other agents against amoebiasis and other protozoal diseases
FDA EPC N0000175485 Antiprotozoal
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000977 Antiparasitic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Giardiasis indication 58265007 DOID:10718
Infection by Cryptosporidium indication 58777003
Coronavirus infection off-label use 186747009
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.29 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Aldose reductase Enzyme IC50 5.09 CHEMBL
Anoctamin-1 Ion channel IC50 6.37 CHEMBL
Signal transducer and activator of transcription 3 Transcription factor IC50 5.01 CHEMBL
Pyruvate dehydrogenase [NADP(+)] Enzyme INHIBITOR DRUGBANK CHEMBL
Pyruvate:ferredoxin oxidoreductase Enzyme INHIBITOR CHEMBL CHEMBL
Pyruvate-flavodoxin oxidoreductase Enzyme Ki 4.98 CHEMBL

External reference:

IDSource
4021365 VUID
N0000148784 NUI
D02486 KEGG_DRUG
4021365 VANDF
C0068788 UMLSCUI
CHEBI:94807 CHEBI
CHEMBL1401 ChEMBL_ID
DB00507 DRUGBANK_ID
C041747 MESH_SUPPLEMENTAL_RECORD_UI
41684 PUBCHEM_CID
5007 INN_ID
SOA12P041N UNII
31819 RXNORM
17040 MMSL
189467 MMSL
d04826 MMSL
006303 NDDF
407148001 SNOMEDCT_US
407149009 SNOMEDCT_US
NTI PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
N/A HUMAN PRESCRIPTION DRUG LABEL 1 43386-405 TABLET 500 mg ORAL NDA authorized generic 24 sections
Nitazoxanide Human Prescription Drug Label 1 64980-526 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
Nitazoxanide Human Prescription Drug Label 1 64980-526 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
Alinia HUMAN PRESCRIPTION DRUG LABEL 1 67546-111 TABLET 500 mg ORAL NDA 24 sections
Alinia HUMAN PRESCRIPTION DRUG LABEL 1 67546-212 POWDER, FOR SUSPENSION 100 mg ORAL NDA 24 sections